Patents by Inventor Paul R. Fatheree

Paul R. Fatheree has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • JAK inhibitors containing a 4-membered heterocyclic amide
    Patent number: 11878977
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: August 10, 2022
    Date of Patent: January 23, 2024
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Melanie A. Kleinschek, Glenn D. Crater
  • JAK kinase inhibitor compounds for treatment of respiratory disease
    Patent number: 11718616
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: March 7, 2022
    Date of Patent: August 8, 2023
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Anne-Marie Beausoleil, Gary E. L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Pierre-Jean Colson, Gene Timothy Fass, Miroslav Rapta, Noah Benjamin, Marta Dabros, Venkat R. Thalladi
  • Fused imidazo-piperidine JAK inhibitors
    Patent number: 11667637
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: June 6, 2023
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Melanie A. Kleinschek, Glenn D. Crater
  • SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS
    Publication number: 20230141212
    Abstract: The disclosure herein provides compounds and pharmaceutical compositions of the structure of Formula I: for the modulation of IL-17A, useful for the treatment of inflammatory conditions, such as psoriasis.
    Type: Application
    Filed: December 28, 2022
    Publication date: May 11, 2023
    Inventors: Paul R. FATHEREE, Martin S. LINSELL, John R. JACOBSEN, Wouter A. VAN DER LINDEN, Timothy J. CHURCH, Claudio AQUINO, Margot G. PAULICK
  • SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS
    Publication number: 20230145481
    Abstract: The disclosure herein provides compounds and pharmaceutical compositions of the structure of Formula I: for the modulation of IL-17A, useful for the treatment of inflammatory conditions, such as psoriasis.
    Type: Application
    Filed: December 28, 2022
    Publication date: May 11, 2023
    Inventors: Paul R. FATHEREE, Martin S. LINSELL, John R. JACOBSEN, Wouter A. VAN DER LINDEN, Timothy J. CHURCH, Claudio AQUINO, Margot G. PAULICK
  • JAK INHIBITORS CONTAINING A 4-MEMBERED HETEROCYCLIC AMIDE
    Publication number: 20230063643
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: August 10, 2022
    Publication date: March 2, 2023
    Inventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN, MELANIE A. KLEINSCHEK, GLENN D. CRATER
  • IL-17 LIGANDS AND USES THEREOF
    Publication number: 20230053746
    Abstract: Provided herein are novel ligands and pharmaceutical compositions thereof which modulate IL-17A. Also provided are methods for preparing the IL-17A modulators. Such compounds may be useful in the treatment and/or prevention of, for example, inflammation, cancer or autoimmune disease.
    Type: Application
    Filed: July 15, 2022
    Publication date: February 23, 2023
    Inventors: Paul R. FATHEREE, Martin S. LINSELL, John R. JACOBSEN, Wouter VAN DER LINDEN, Timothy J. CHURCH, Claudio AQUINO, Margot PAULICK
  • JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE
    Publication number: 20220306624
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: March 7, 2022
    Publication date: September 29, 2022
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Anne-Marie Beausoleil, Gary E.L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D.E. Sullivan, Lori Jean Van Orden, Pierre-Jean Colson, Gene Timothy Fass, Miroslav Rapta, Noah Benjamin, Marta Dabros, Venkat R. Thalladi
  • JAK inhibitors containing a 4-membered heterocyclic amide
    Patent number: 11453668
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: September 27, 2022
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden
  • IL-17 ligands and uses thereof
    Patent number: 11447468
    Abstract: Provided herein are novel ligands and pharmaceutical compositions thereof which modulate IL-17A. Also provided are methods for preparing the IL-17A modulators. Such compounds may be useful in the treatment and/or prevention of, for example, inflammation, cancer or autoimmune disease.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: September 20, 2022
    Assignee: DICE ALPHA, INC.
    Inventors: Paul R. Fatheree, Martin S. Linsell, John R. Jacobsen, Wouter Van der Linden, Timothy J. Church, Claudio Aquino, Margot Paulick
  • FUSED IMIDAZO-PIPERIDINE JAK INHIBITORS
    Publication number: 20220289737
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: January 14, 2022
    Publication date: September 15, 2022
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Melanie A. Kleinschek, Glenn D. Crater
  • BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS
    Publication number: 20220274957
    Abstract: The invention relates to benzimidazole-carboxamide 5-HT4 receptor agonist compounds of formula (I) wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: January 12, 2022
    Publication date: September 1, 2022
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Robert Murray McKinnell, Roland Gendron, Lan Jiang, Seok-Ki Choi, Daniel D. Long, Paul R. Fatheree, Daniel Marquess
  • SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS
    Publication number: 20220235038
    Abstract: The disclosure herein provides compounds and pharmaceutical compositions of the structure of Formula I: for the modulation of IL-17A, useful for the treatment of inflammatory conditions, such as psoriasis.
    Type: Application
    Filed: January 27, 2022
    Publication date: July 28, 2022
    Inventors: Paul R. FATHEREE, Martin S. LINSELL, John R. JACOBSEN, Wouter A. VAN DER LINDEN, Timothy J. CHURCH, Claudio AQUINO, Margot G. PAULICK
  • JAK kinase inhibitor compounds for treatment of respiratory disease
    Patent number: 11299492
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: April 12, 2022
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Gary E. L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Anne-Marie Beausoleil
  • Substituted benzenecarboxamides as IL-17A modulators
    Patent number: 11274094
    Abstract: The disclosure herein provides compounds and pharmaceutical compositions for the modulation of IL-17A useful for the treatment of inflammatory conditions, such as psoriasis.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: March 15, 2022
    Assignee: DICE ALPHA, INC.
    Inventors: Paul R. Fatheree, Martin S. Linsell, John R. Jacobsen, Wouter A. Van Der Linden, Timothy J. Church, Claudio Aquino, Margot G. Paulick
  • Fused imidazo-piperidine JAK inhibitors
    Patent number: 11254669
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: February 22, 2022
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden
  • FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND
    Publication number: 20220008428
    Abstract: The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes and intermediates useful for preparing the compound.
    Type: Application
    Filed: September 28, 2021
    Publication date: January 13, 2022
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: PAUL R. FATHEREE, LAN JIANG
  • Fused imidazo-piperidine JAK inhibitor compound
    Patent number: 11160810
    Abstract: The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes and intermediates useful for preparing the compound.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: November 2, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Robert Murray McKinnell, Venkat R. Thalladi, Hao Zhang, Paul R. Fatheree, Lan Jiang, Marta Dabros, Jerry Nzerem
  • Pyrimidine compounds as JAK kinase inhibitors
    Patent number: 11110095
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: September 7, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Ryan Hudson, Jennifer Kozak, Melissa Fleury, Paul R. Fatheree, Anne-Marie Beausoleil, Dante D. Podesto, Xiaojun Huang
  • JAK INHIBITORS CONTAINING A 4-MEMBERED HETEROCYCLIC AMIDE
    Publication number: 20210269436
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: February 12, 2021
    Publication date: September 2, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN